Case studies
Engagements we're proud of, with the names removed. Happy to walk through any of these in person.
Top-10 global pharma
A pre-launch oncology asset needed a defensible patient-based forecast spanning four indications and three competitive scenarios.
peak-year revenue forecast accepted by finance
Mid-cap specialty pharma
Brand teams were stitching together TRx, claims, and field data manually each month, losing days to reconciliation.
reduction in monthly reporting cycle time
Top-20 pharma, immunology
A maturing immunology brand was overspending on declining segments and under-covering emerging high-value HCPs.
lift in high-value HCP reach within 2 quarters